Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selective Bladder-Sparing Trial with Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

NCT06623162 is registered in ClinicalTrials.gov with Fundación de investigación HM as lead sponsor.

NCT NCT06623162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06623162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selective Bladder-Sparing Trial with Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients
Lead sponsor
Fundación de investigación HM
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2024
Completion date
December 31, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mibc, muscle invasive bladder cancer